Pharmacokinetic Drug Interactions of Morphine, Codeine, and Their Derivatives: Theory and Clinical Reality, Part II

Psychosomatics

Volumn 44, Issue 6, 2003, Pages 515-520

  Armstrong, Scott C ^a,b   Cozza, Kelly L ^c,d  

^a Tuality Forest Grove Hospital   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CODEINE; CYTOCHROME P450; DEXTROPROPOXYPHENE; DIHYDROCODEINE; GLUCURONOSYLTRANSFERASE; HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; MORPHINE; OXYCODONE; OXYMORPHONE; PERCOCET; PETHIDINE; PRODRUG;

ANALGESIA; DOSE RESPONSE; DRUG ACTIVITY; DRUG CONJUGATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; OXIDATION; REVIEW;

EID: 0242299162     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.44.6.515     Document Type: Article

References (34)

1. Armstrong SC, Cozza KL: Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics 2003; 44:167-171
2. Pert CB, Snyder SH: Opiate receptor, demonstration in nervous tissue. Science 1973; 179:1101-1104
3. Sanfilippo G: Contributo sperimentale all'ipotesi della smetilazione della codeina nella organismo. I. Influence della dose sulll'assuefazione all codeine. II. Assuefazione all codeine attenuta con somministrazione prolungata di morfina. Boll Soc Italiana Biol Sper 1948;24:723-726
4. Sindrup SH, Brosen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR, Gram LF: Codeine increases pain thresholds to copper vapour laser stimuli in extensive but not in poor metabolisers of sparteine. Clin Pharmacol Ther 1990; 48:686-693
5. Desmeules J, Gascon MP, Dayer P, Magistris M: Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41:23-26
6. Vree TB, Verwey-van Wissen CP: Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Dispos 1992; 13:445-460
7. Quiding H, Lundqvist G, Boreus LO, Bondesson U, Ohrvik J: Analgesic effect and plasma concentrations of codeine and morphine after two dose levels of codeine following oral surgery. Eur J Clin Pharmacol 1993; 44:319-323
8. Persson K, Sjostrom S, Sigurdardottir I, Molnar V, Hammarlund-Udenaes M, Rane A: Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. Br J Clin Pharmacol 1995; 39:182-186
9. Poulsen L, Riishede L, Brosen K, Clemensen S, Sindrup SH: Codeine in post-operative pain: study of the influence of sparteine phenotype and serum concentrations of morphine and morhine-6-glucuronide. Eur J Clin Pharmacol 1998; 54:451-454
10. Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, Sellers EM, Romach MK: Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. J Clin Psychopharmacol 2002; 22:326-329
11. Kathiramalainathan K, Kaplan HL, Romach MK, Busto UE, Li NY, Sawe J, Tyndale RF, Sellers EM: Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. J Clin Psychopharmacol 2000; 20:435-444
12. Vree TB, Van Dongren RT, Koopman-Kimenai PM: Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract 2000; 54:395-398
13. Mignat C, Wille U, Ziegler A: Affinity profiles of morphine, codeine, dihydrocodeine and the glucuronides at the opioid receptor subtypes. Life Sci 1995; 56:793-799
14. Srinivasan V, Wielbo D, Simpkins J, Karlix J, Sloan K, Tebbett I: Analgesic and immunomodulatory effects of codeine and codeine-6-glucuronide. Pharm Res 1996; 13:296-300
15. Cozza KL, Armstrong SC, Oesterheld JH: Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, UGTs, P-glycoproteins, 2nd edition. Arlington, Va, American Psychiatric Publishing. 2003
16. Grancharov K, Naydenova Z, Lozeva S, Golovinsky E: Natural and synthetic inhibitors of UDP-glucuronosyltransferase. Pharmacol Ther 2001; 89:171-186
17. Ammon S, Marx C, Behrens C, Hofmann U, Murdter T, Griese EU, Mikus G: Diclofenac does not interact with codeine metabolism in vivo: study in healthy volunteers. BMC Clin Pharmacol 2002; 2:2 (http://www.biomedcentral.com/1472-6904/2/2)
18. Case LJ, Frederick WS: An experimental and statistical method in the study of new drugs. Arch Int Med 1958; 102:571-580
19. Schmidt H, Vormfelde SV, Walchner-Bonjean M, Klinder K, Freudenthaler S, Gleiter CH, Gundert-Remy U, Skopp G, Aderjan R, Fuhr U: The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther 2003; 41:95-106
20. Kirkwood LC, Nation RL, Somogyi AA: Characterization in the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. Br J Clin Pharmacol 1997; 44:549-555
21. Balikova M, Maresova V, Habrdova V: Evaluation of urinary dihydrocodeine excretion in human by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2001; 752:179-186
22. Kirkwood LC, Nation RL, Somogyi AA: Glucuronidation of dihydrocodeine by human liver microsomes and the effect of inhibitors. Clin Exp Pharmacol Physiol 1998; 25:266-270
23. Wilder-Smith CH, Hufschmid E, Thorman W: The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine: a cross-over study with extensive and quinidine-induced poor metabolizers. Br J Pharmacol 1998; 45:575-581
24. Webb JA, Rostami-Hodjegan A, Abdul-Manap R, Hofmann U, Mikus G, Kamali F: Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modeling analysis. Br J Clin Pharmacol 2001; 52:35-43
25. Chen ZR, Irvine RJ, Somogyi AA, Bochner F: Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48:2165-2171
26. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM: Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53:401-409
27. Cone EJ, Darwin WD, Gorodetzky CW, Tan T: Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog. Drug Metab Dispos 1978; 6:488-493
28. Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, Sellers EM: Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 1997; 281:103-108
29. Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppala T: Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 1990; 67:322-328
30. Heiskanen T, Olkkola KT, Kalso E: Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64:603-611
31. Jannetto PJ, Wong SH, Gock SB, Laleli-Sahin E, Schur BC, Jentzen JM: Pharmacogenomics as molecular autopsy for postmortem forensic toxicology; genotyping cytochrome P450 2D6 for oxycodone cases. J Anal Toxicol 2002; 26:438-447
32. Drummer OH, Syrjanen ML, Phelan M, Cordner SM: A study of deaths involving oxycodone. J Forensic Sci 1994; 39:1069-1075
33. Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, Kuroiwa Y: Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 1998; 26:818-821
34. Buprenexr® (Buprenorphine hydrochloride). Hull, England, Rickett Benckiser Healthcare (UK) Ltd, July 2001